CRISPR gene-editing therapy safely and continuously lowers cholesterol and triglycerides, first-in-human trial shows
3 Articles
3 Articles
A novel gene therapy may help control high cholesterol levels with a single treatment. In a recent phase 1 trial, CTX310, which altered genes in liver cells, reduced LDL cholesterol levels in patients by nearly half and the effect lasted for at least a year.
The idea of a genetic editing treatment arose from an unusual source - a genetic mutation in the ANGPTL3 gene, or angiopoietin-like protein 3 gene, responsible for the regulation of LDL and triglycerides
CRISPR gene-editing therapy safely and continuously lowers cholesterol and triglycerides, first-in-human trial shows
CRISPR gene-editing therapy safely and continuously lowers cholesterol and triglycerides, first-in-human trial shows A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL ("bad")…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
